Severe Insulin Resistance with Diabetic Ketoacidosis After Brentuximab Treatment
ABSTRACT: Objective: To increase awareness of unusual inflammatory and other responses including severe insulin resistance (IR) associated with the use of targeted immunotherapies such as brentuximab. Methods: We report the case of a man without any previous diagnosis of diabetes who developed diab...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | AACE Clinical Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060520300559 |
| Summary: | ABSTRACT: Objective: To increase awareness of unusual inflammatory and other responses including severe insulin resistance (IR) associated with the use of targeted immunotherapies such as brentuximab. Methods: We report the case of a man without any previous diagnosis of diabetes who developed diabetic ketoacidosis complicated by severe IR (unresponsive to >600 units of intravenous insulin per hour) after receiving brentuximab for Hodgkin lymphoma. Results: Autoantibodies to the insulin receptor were not detected in the patient's serum, thus excluding a diagnosis of type B IR. Conclusion: We hypothesize that brentuximab administration led to a rare reaction leading to systemic cytokine release with extreme IR in our patient. |
|---|---|
| ISSN: | 2376-0605 |